17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Inclusion Criteria

• •Histologically confirmed diagnosis of solid tumor or leukemia with documented M3 marrow
• •* Histologic confirmation of intrinsic brain stem tumors not required
• •Relapsed or refractory disease
• •No known curative therapy
• •In patients with CNS tumors, neurologic deficits must be stable for at least the past week
• •Performance status - Karnofsky 50-100% (\>10 years of age)
• •Performance status - Lansky 50-100% (≤ 10 years of age)
• •For patients with solid tumors:
• •* Absolute neutrophil count ≥ 1,000/mm\^3
• •* Platelet count ≥ 100,000/mm\^3 (transfusion independent)
• •* Hemoglobin ≥ 8.0 g/dL (may receive RBC transfusions)
• •For patients with leukemia:
• •* Platelet count ≥ 20,000/mm\^3 (may receive platelet transfusions)
• •* Hemoglobin ≥ 8.0 g/dL (may receive RBC transfusions)
• •Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• •ALT ≤ 2.5 times ULN
• •Albumin ≥ 2 g/dL
• •Creatinine clearance OR radioisotope glomerular filtration rate ≥ 70 mL/min
• •Creatinine based on age as follows:
• •* ≤ 0.8 mg/dL if ≤ 5 years of age
• •* ≤ 1.0 mg/dL if \> 5 years and ≤ 10 years of age
• •* ≤ 1.2 mg/dL if \> 10 years and ≤ 15 years of age
• •* ≤ 1.5 mg/dL if \> 15 years and ≤ 21 years of age
• •No uncontrolled infection
• •No prior severe allergy to eggs
• •No situation that would preclude study participation
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •At least 7 days (or window for adverse effects has passed) since prior biologic therapy and recovered
• •At least 7 days since prior hematopoietic growth factors
• •At least 2 months since prior stem cell transplantation and no evidence of graft-vs-host disease
• •No concurrent hematopoietic growth factors
• •No concurrent biologic therapy
• •No concurrent immunotherapy
• •At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) and recovered
• •No other concurrent chemotherapy
• •No concurrent steroid therapy
• •At least 2 weeks since prior local palliative radiotherapy (small port)
• •At least 3 months since prior total body irradiation or craniospinal radiotherapy
• •At least 3 months since prior radiotherapy to ≥ 50% of the pelvis
• •At least 6 weeks since prior substantial bone marrow radiotherapy
• •Recovered from prior radiotherapy
• •No concurrent radiotherapy
• •No other concurrent investigational drugs
• •No other concurrent anticancer agents
• •No concurrent phenytoin or phenobarbital
• •No concurrent warfarin